Weta Digital Partners With Autodesk to Offer Next Generation Creative Cloud Production Pipeline
Weta Digital, one of the world’s premiere visual effects studios, has partnered with global media and entertainment software provider, Autodesk, Inc. (NASDAQ: ADSK), to launch WetaM - a ground breaking product offering that provides tools designed and developed by Weta Digital, fully embedded in Autodesk Maya. Weta Digital has won 13 Academy Sci-tech Awards for its tools that helped artists produce some of the most successful film and TV series in the world, including “The Lord of the Rings,” “Avatar,” “Game of Thrones,” and “Planet of the Apes,” to name a few. Weta intends to rollout WetaM as a private beta in Q4.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210617005301/en/
Planet of the Apes Copyright:© 2017 Twentieth Century Fox Film Corporation (Photo: Business Wire)
WetaM productizes Weta’s unique set of proprietary VFX tools for artists built on Maya’s open API, and will be commercialized by Weta Digital as a subscription cloud service. For the first time, artists from around the world will have access to one complete—from stage to screen—cloud based pipeline. The launch of WetaM marks the first product launch under a newly formed Software-as-a-Service (SaaS) division within Weta Digital. This new business arm is an integral part of Weta’s expansion strategy to offer professional and prosumer tools to artists across the global entertainment industry.
“WetaM is the first step in the democratization of VFX and animation production. Weta Digital brings together the most creative minds in the world and has been a pioneering innovator in the visual effects and entertainment industry for decades,” said Prem Akkaraju, CEO of Weta Digital. “WetaM is a transformational move that will raise the bar for global creative production, redefining the industry in the process. At its core, this partnership with Autodesk will extend the reach of the Weta magic, making it more accessible for artists in pursuit of creating amazing characters and worlds across film and television.”
“We are longtime fans of Weta’s remarkable visual effects achievements, and they are constantly breaking new ground building immersive, imaginary worlds and unbelievably real and engaging digital characters,” said Diana Colella, senior vice president, Entertainment & Media Solutions, Autodesk. “The debut of WetaM is a gamechanger as it opens up years of Weta’s dedicated animation and VFX R&D resources to all creatives. It is exciting to be working with Weta to bring their magic to Maya artists, offering them powerful new effects tools and time-saving automation capabilities.”
As a leader in VFX and animation for the last three decades, Weta Digital’s DNA is rooted in technological innovation, unmatched artistic talent and exceptional visual style. Brought to life through the partnership with Autodesk, WetaM shares this DNA and gives artists, everywhere, access to the unique visual design and pipeline efficiency tools that have driven Weta Digital’s Academy® Award-winning success.
ABOUT WETA DIGITAL
Weta Digital is the standard-bearer for creativity and innovation in visual effects and animation, attracting talent, partners, and clients that seek to push what is possible in pursuit of their artistic vision. Weta’s proprietary pipeline continues to evolve and provide artists with the tools they need to create their best work. Based in Wellington, New Zealand, Weta Digital is the largest single-site VFX studio in the world drawing artists from over 40 countries. They are some of the most creative and ambitious artists, engineers, and executives in entertainment and their work has earned six visual effects Academy Awards, ten Academy Sci-Tech Awards and six visual effects BAFTA Awards in addition to the 34 Visual Effects Society Awards awarded to them by their peers. Ground-breaking, performance-driven animated characters from Gollum to Caesar, and worlds from Middle-earth to Pandora, are regarded as some of the best visual effects ever to appear on screen.
For more information:
Weta Digital: www.wetafx.co.nz
Follow: @weta_digital
ABOUT AUTODESK
Autodesk makes software for people who make things. If you've ever driven a high-performance car, admired a towering skyscraper, used a smartphone, or watched a great film, chances are you've experienced what millions of Autodesk customers are doing with our software. Autodesk gives you the power to make anything. For more information, visit www.autodesk.com or follow @autodesk.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210617005301/en/
Contact information
PRESS:
Weta Digital | Mara Buxbaum, ID | TeamWetaDigital@id-pr.com
Weta Digital | Carol Marshall | carolm@wetafx.co.nz
Autodesk | Karen Raz, RazPR | karen@razpr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IMEC Achieves a World-record GaN Breakdown Voltage Exceeding 650 V on Shin-Etsu Chemical’s 300-mm QST™ Substrate13.11.2025 06:00:00 EET | Press release
The QSTTM substrate*1, a 300-mm GaN growth substrate that Shin-Etsu Chemical Co., Ltd. (Head Office: Tokyo; President: Yasuhiko Saitoh; hereinafter, “Shin-Etsu Chemical”) developed, has been adopted for the 300-mm GaN power device development program at IMEC*2, where sample evaluation is in progress. In the evaluation, the 5 µm-thick HEMT*3 device using a QSTTM substrate achieved a record-breaking voltage resistance exceeding 650 V for a 300mm substrate. Shin-Etsu Chemical, licensed by QROMIS, Inc. (Head office: CA, U.S.A, CEO: Cem Basceri, hereafter "QROMIS"), manufactures 150-mm and 200-mm QST™ substrates, as well as GaN-on-QST™ epitaxial substrates of various diameters. In September 2024, we started providing 300-mm QST™ samples in a joint initiative with QROMIS. Furthermore, Shin-Etsu Chemical and QROMIS have established a close partnership to provide 300-mm QST™ substrates for the state-of-the-art 300-mm CMOS fab of IMEC, which is based in Leuven, Belgium. IMEC is a 300-mm GaN pow
DBS and Ant International Enhance Strategic Partnership to Scale Innovative Cross-Border Payment and Fintech Solutions to Drive Inclusive Growth13.11.2025 05:00:00 EET | Press release
DBS and Ant International have agreed to deepen their existing strategic collaboration to jointly explore innovative payments, digitisation and fintech solutions aimed at providing more inclusive services for regional businesses of all sizes and individual consumers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251112714266/en/ From left to right: Tan Su Shan, CEO of DBS, Loy Hwee Chuan, Segment Head of Telecommunications, Media & Tech, Hong Kong and GBA, DBS, Edward Yue, Alipay+ General Manager for SEA, ANZ and South Asia at Ant International, Peng Yang, CEO of Ant International The collaboration will leverage DBS’ digital banking capabilities and Ant International’s cutting-edge financial technologies such as AI and blockchain, to scale cross-border payments, strengthen connectivity and drive innovations in the financial ecosystem. The Memorandum of Understanding (MoU) was inked on the sidelines of the Singapore Fintech
LabGenius Therapeutics Announces Poster Presentation at the ESMO Immuno-Oncology Congress 202513.11.2025 02:00:00 EET | Press release
LabGenius Therapeutics (“LabGenius”), a drug discovery company combining artificial intelligence (AI) and high-throughput experimentation to advance next-generation multispecific antibodies for solid tumours, today announced a scientific poster will be presented at the ESMO Immuno-Oncology Congress 2025, being held December 10 - 12, 2025, at the Queen Elizabeth II Centre in London, United Kingdom. LabGenius’ presentation will debut the pre-clinical in vivo efficacy (>90% tumour growth inhibition) and tolerability data for their lead asset, a highly tumour selective bispecific T-cell engager (TCE). Poster Presentation Details Title Novel Selectivity-Enhanced Bispecific T-cell Engager Utilises Avidity to Overcome On-target, Off-tumour Toxicity Date and time Wednesday, December 10, 2025, 08:00 (GMT) Poster number 309P Location The Churchill Room, Queen Elizabeth II Centre, London Bispecific TCE Overview For the selected target, LabGenius has developed a selectivity-enhanced TCE. The compa
VeriSilicon and Google Jointly Launch Open-Source Coral NPU IP13.11.2025 02:00:00 EET | Press release
VeriSilicon (688521.SH) recently announced the joint launch of the Coral NPU IP with Google, targeting always-on, ultra-low-energy edge Large Language Model (LLM) applications. The IP is based on Google’s foundational research in open machine learning compilers and enhanced with AI security features, providing developers with a unified open-source platform to build a robust edge AI ecosystem. The Coral NPU is built on the open RISC-V instruction set architecture, featuring native tensor processing capabilities, supporting mainstream machine learning frameworks such as JAX, PyTorch, and TensorFlow Lite (TFLite), and utilizing open-standard tools like Multi-Level Intermediate Representation (MLIR) from the Low Level Virtual Machine (LLVM) project for compiler infrastructure. It is designed for always-on, ultra-low-energy edge AI applications, particularly for wearable devices and ambient sensing systems. The Coral NPU IP is now open-sourced on the Google Developers website and available
Indero Announces Breakthrough Method for Early-Phase Evaluation of Topical Drugs Using Quantitative Gene Expression13.11.2025 01:00:00 EET | Press release
Indero is proud to announce the successful completion of an internally funded study that introduces a novel approach to evaluating topical new chemical entities (NCE) in early-phase clinical research. This innovative method leverages quantitative gene expression analysis to assess drug efficacy rapidly and cost effectively. Dr. Robert Bissonnette, Executive Chairman and Founder of Indero, who initiated and led the study, shared his excitement about the results: “Our goal was to rethink how to study topical drugs in early phase studies. The results of this study demonstrate that microdosing for only 3 days can provide meaningful efficacy signals. Within just 24 hours, we observed alterations in gene expression after applying a microdose of mid-potency corticosteroid on the skin of patients. By 72 hours, Th2, Th22 and Th17-specific biomarkers were significantly reduced. This outcome is exactly what we hoped for and opens the door to faster, smarter drug development strategies, demonstrat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom